Elon Musk's company Neuralink is set to implant the new Blindsight chip, designed to restore vision, into a human patient for the first time in late 2025.
Experimental Vision-Restoring Chip
Blindsight is being developed to restore sight to completely blind individuals by stimulating the visual cortex, bypassing optical nerves. Initially, the device will provide low-resolution images, but over time, its potential could surpass natural vision, allowing for the perception of infrared, ultraviolet, and radar wavelengths.
Feedback and Comparisons
Critics have pointed out possible exaggeration in the significance of Neuralink's achievement. Experts have mentioned other successful examples, like Argus II, which faced market issues. Gislin Dagnelie from Johns Hopkins University highlighted the lack of published pre-clinical results from Neuralink.
Reaction and Development Prospects
The technology is intriguing and is seen as an addition to a cane and guide dog rather than a replacement. Philip Troyk from the Illinois Institute of Technology thinks the chip's potential is high. Despite criticism, the project is supported due to its innovative nature.
Neuralink continues to develop the ambitious vision-restoration project. The first clinical experience is expected to open new prospects in neurology and rehabilitation.
